21‑Gene recurrence score influences the chemotherapy decision for patients with breast cancer of different luminal subtypes

Wang,Wei; Lin,Lin; Fei,Xiaochun; Hong,Jin; Gao,Weiqi; Zhu,Siji; Wu,Jiayi; Huang,Ou; He,Jianrong; Li,Yafen; Zhu,Li; Chen,Weiguo; Chen,Xiaosong; Shen,Kunwei

doi:10.3892/ol.2019.10766

21‑Gene recurrence score influences the chemotherapy decision for patients with breast cancer of different luminal subtypes

Authors:
- Wei Wang
- Lin Lin
- Xiaochun Fei
- Jin Hong
- Weiqi Gao
- Siji Zhu
- Jiayi Wu
- Ou Huang
- Jianrong He
- Yafen Li
- Li Zhu
- Weiguo Chen
- Xiaosong Chen
- Kunwei Shen
View Affiliations

Affiliations: Department of Breast Surgery, Comprehensive Breast Health Center, Shanghai Jiaotong University School of Medicine, Shanghai 200025, P.R. China, Department of Clinical Laboratory, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, P.R. China, Department of Pathology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, P.R. China
Published online on: August 16, 2019 https://doi.org/10.3892/ol.2019.10766
Pages: 4346-4356

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Luminal subtypes and the 21‑gene recurrence score (RS) are important factors in the decision‑making process for adjuvant chemotherapy in patients with hormonal receptor (HR)‑positive/human epidermal growth factor receptor 2 (HER2)‑negative breast cancer. However, their effect on adjuvant chemotherapy decisions in the real world has not been thoroughly investigated, particularly for patients of the luminal A‑like subtype with a high RS or the luminal B‑like subtype with a low RS. The present study, a total of 772 HR+/HER2‑ patients who underwent 21‑gene testing, were included in a retrospective analysis. The impact of clinicopathological factors and the 21‑gene RS on chemotherapy recommendation was analyzed in the whole population and for patients of different luminal subgroups. The results revealed that chemotherapy was highly recommended for patients of younger age, with larger tumor size, node involvement, higher grade, luminal B‑like subtype and higher RS. A high RS was identified to be the most important impact factor for chemotherapy recommendation among all patients [odds ratio (OR), 62.54; 95% CI, 25.58‑152.92], the luminal A‑like group (OR, 435.05; 95% CI, 29.90‑6331.06) and the luminal B‑like group (OR, 57.20; 95% CI, 22.42‑145.96). For patients of the luminal A‑like subtype with a high RS or patients of the luminal B‑like subtype with low RS, the 21‑gene RS was demonstrated to be the most important independent factor for chemotherapy recommendation, with an adjusted OR of 134.52 (95% CI, 10.39‑1741.89). In conclusion, luminal subtypes and the 21‑gene RS were found to be associated with chemotherapy recommendation for HR+/HER2‑ patients. For patients with a discordant luminal subtype and 21‑gene RS risk, the 21‑gene RS score was found to be the most important factor that influences chemotherapy decision, which warrants further clinical evaluation.

View Figures

View References

1	Zheng RS, Sun KX, Zhang SW, Zeng HM, Zou XN, Chen R, Gu XY, Wei WW and He J: Report of cancer epidemiology in China, 2015. Zhonghua Zhong Liu Za Zhi. 41:19–28. 2019.(In Chinese; Abstract available in Chinese from the publisher). PubMed/NCBI
2	Early Breast Cancer Trialists' Collaborative Group (EBCTCG), . Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of randomized trials. Lancet. 365:1687–1717. 2005. View Article : Google Scholar : PubMed/NCBI
3	Silberholz J, Bertsimas D and Vahdat L: Clinical benefit, toxicity and cost of metastatic breast cancer therapies: Systematic review and meta-analysis. Breast Cancer Res Treat. 176:535–543. 2019. View Article : Google Scholar : PubMed/NCBI
4	Alarid-Escudero F, Blaes AH and Kuntz KM: Trade-offs between efficacy and cardiac toxicity of adjuvant chemotherapy in early-stage breast cancer patients: Do competing risks matter? Breast J. 23:401–409. 2017. View Article : Google Scholar : PubMed/NCBI
5	De Abreu FB, Schwartz GN, Wells WA and Tsongalis GJ: Personalized therapy for breast cancer. Clin Genet. 86:62–67. 2014. View Article : Google Scholar : PubMed/NCBI
6	Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, Thürlimann B and Senn HJ; Panel Members, : Tailoring therapies-Improving the management of early breast cancer: St gallen international expert consensus on the primary therapy of early breast cancer 2015. Ann Oncol. 26:1533–1546. 2015. View Article : Google Scholar : PubMed/NCBI
7	Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B and Senn HJ; Panel members, : Strategies for subtypes-dealing with the diversity of breast cancer: Highlights of the st gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol. 22:1736–1747. 2011. View Article : Google Scholar : PubMed/NCBI
8	Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Perez EA, Olson JA Jr, et al: Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med. 373:2005–2014. 2015. View Article : Google Scholar : PubMed/NCBI
9	Gluz O, Nitz UA, Christgen M, Kates RE, Shak S, Clemens M, Kraemer S, Aktas B, Kuemmel S, Reimer T, et al: West German Study Group Phase III PlanB trial: First prospective outcome data for the 21-gene recurrence score assay and concordance of prognostic markers by central and local pathology assessment. J Clin Oncol. 34:2341–2349. 2016. View Article : Google Scholar : PubMed/NCBI
10	Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 351:2817–2826. 2004. View Article : Google Scholar : PubMed/NCBI
11	Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D, Bryant J, et al: Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 24:3726–3734. 2006. View Article : Google Scholar : PubMed/NCBI
12	Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, Ravdin P, Bugarini R, Baehner FL, Davidson NE, et al: Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: A retrospective analysis of a randomised trial. Lancet Oncol. 11:55–65. 2010. View Article : Google Scholar : PubMed/NCBI
13	Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Goetz MP, Olson JA Jr, et al: Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 379:111–121. 2018. View Article : Google Scholar : PubMed/NCBI
14	Network NCC, . NCCN Clinical Practice Guidlines in Oncology. Breast Cancer. Version 2.2017. http://www.nccn.org/professionals/physician_gls/pdf/breast_blocks.pdfApril 6–2017
15	Hornberger J, Alvarado MD, Rebecca C, Gutierrez HR, Yu TM and Gradishar WJ: Clinical validity/utility, change in practice patterns, and economic implications of risk stratifiers to predict outcomes for early-stage breast cancer: A systematic review. J Natl Cancer Inst. 104:1068–1079. 2012. View Article : Google Scholar : PubMed/NCBI
16	Habel LA, Shak S, Jacobs MK, Capra A, Alexander C, Pho M, Baker J, Walker M, Watson D, Hackett J, et al: A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res. 8:R252006. View Article : Google Scholar : PubMed/NCBI
17	Dowsett M, Cuzick J, Wale C, Forbes J, Mallon EA, Salter J, Quinn E, Dunbier A, Baum M, Buzdar A, et al: Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: A TransATAC study. J Clin Oncol. 28:1829–1834. 2010. View Article : Google Scholar : PubMed/NCBI
18	Toi M, Iwata H, Yamanaka T, Masuda N, Ohno S, Nakamura S, Nakayama T, Kashiwaba M, Kamigaki S and Kuroi K; Japan Breast Cancer Research Group-Translational Research Group, : Clinical significance of the 21-gene signature (Oncotype DX) in hormone receptor-positive early stage primary breast cancer in the Japanese population. Cancer. 116:3112–3118. 2010. View Article : Google Scholar : PubMed/NCBI
19	Van der Hoeven JJ: 70-Gene signature as an aid to treatment decisions in early-stage breast cancer. Ned Tijdschr Geneeskd. 161:D13692017.(In Dutch). PubMed/NCBI
20	Charlson ME, Pompei P, Ales KL and MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis. 40:373–383. 1987. View Article : Google Scholar : PubMed/NCBI
21	Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B and Senn HJ; Panel members, : Personalizing the treatment of women with early breast cancer: Highlights of the st gallen international expert consensus on the primary therapy of early breast cancer 2013. Ann Oncol. 24:2206–2223. 2013. View Article : Google Scholar : PubMed/NCBI
22	Lakhani SR, Ellis IO, Schnitt SJ, Tan PH and van de Vijver MJ: WHO classification of tumours of the breastWorld Health Organization Classification of Tumours. 4th. International Agency for Research on Cancer; Lyon: pp. 60–61. 2012
23	Edge S, Byrd D and Compton C: AJCC Cancer Staging Handbook7th. American Joint Committee on Cancer. Springer; New York, NY: 2010, PubMed/NCBI
24	Elston CW and Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology. 19:403–410. 1991. View Article : Google Scholar : PubMed/NCBI
25	Wu J, Fang Y, Lin L, Fei X, Gao W, Zhu S, Zong Y, Chen X, Huang O, He J, et al: Distribution patterns of 21-gene recurrence score in 980 Chinese estrogen receptor-positive, HER2-negative early breast cancer patients. Oncotarget. 8:38706–38716. 2017.PubMed/NCBI
26	Cronin M, Sangli C, Liu ML, Pho M, Dutta D, Nguyen A, Jeong J, Wu J, Langone KC and Watson D: Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer. Clin Chem. 53:1084–1091. 2007. View Article : Google Scholar : PubMed/NCBI
27	Esteban J, Baker J, Cronin M, et al: Tumor gene expression and prognosis in breast cancer: Multi-gene RT-PCR assay of paraffin-embedded tissue. Proc Am Soc Clin Oncol. 22:8502003.
28	Paik S, Shak S, Tang G, et al: Multi-gene RT-PCR assay for predicting recurrence in node negative breast cancer patients: NSABP studies B-20 and B-14. Breast Cancer Res Treat. 82:A162003.
29	Cobleigh MA, Bitterman P, Baker J, et al: Tumor gene expression predicts distant disease-free survival (DDFS) in breast cancer patients with 10 or more positive nodes: High throughout RT-PCR assay of paraffin-embedded tumor tissues. Prog Proc Am Soc Clin Oncol. 22:8502003.
30	Prat A, Cheang MC, Martín M, Parker JS, Carrasco E, Caballero R, Tyldesley S, Gelmon K, Bernard PS, Nielsen TO and Perou CM: Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol. 31:203–209. 2013. View Article : Google Scholar : PubMed/NCBI
31	Harris LN, Ismaila N, McShane LM, Andre F, Collyar DE, Gonzalez-Angulo AM, Hammond EH, Kuderer NM, Liu MC, Mennel RG, et al: Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 34:1134–1150. 2016. View Article : Google Scholar : PubMed/NCBI
32	Arima N, Nishimura R, Osako T, Okumura Y, Nakano M, Fujisue M, Nishiyama Y and Toyozumi Y: Ki-67 index value and progesterone receptor status can predict prognosis and suitable treatment in node-negative breast cancer patients with estrogen receptor-positive and HER2-negative tumors. Oncol Lett. 17:616–622. 2019.PubMed/NCBI
33	Zhu L, Ma N, Wang B, Zhou C, Yan Y, Wang K, He J and Ren Y: Clinical analysis of 21-gene recurrence score test in hormone receptor-positive early-stage breast cancer. Oncol Lett. 17:5469–5480. 2019.PubMed/NCBI
34	Nitz U, Gluz O, Christgen M, Kates RE, Clemens M, Malter W, Nuding B, Aktas B, Kuemmel S, Reimer T, et al: Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: Five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial. Breast Cancer Res Treat. 165:573–583. 2017. View Article : Google Scholar : PubMed/NCBI